Wockhardt Ltd

Sky Gold & Diamonds Ltd, Hindustan Zinc Ltd, HFCL Ltd and National Aluminium Company Ltd are among the other losers in the BSE's 'A' group today, 05 June 2026.Wockhardt Ltd tumbled 7.09% to Rs 1926 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 2.4 lakh shares were traded on the counter so far as against the average daily volumes of 1.96 lakh shares in the past one month.Sky Gold & Diamonds Ltd crashed 6.92% to Rs 531.8. The stock was the second biggest loser in 'A' group.On the BSE, 1.28 lakh shares were traded on the counter so far as against the average daily volumes of 1.38 lakh shares in the past one month.Hindustan Zinc Ltd lost 5.87% to Rs 568.3. The stock was the third biggest loser in 'A' group.On the BSE, 3.36 lakh shares were traded on the counter so far as against the average daily volumes of 2.91 lakh shares in the past one month.HFCL Ltd fell 5.00% to Rs 187.2. The stock was the fourth biggest loser in 'A' group.On the BSE, 24.55 lakh shares were traded on the counter so far as against the average daily volumes of 34.53 lakh shares in the past one month.National Aluminium Company Ltd pared 4.90% to Rs 393.65. The stock was the fifth biggest loser in 'A' group.On the BSE, 3.74 lakh shares were traded on the counter so far as against the average daily volumes of 4.44 lakh shares in the past one month.Powered by Capital Market - Live

Wockhardt Ltd is up for a fifth straight session today. The stock is quoting at Rs 2201.1, up 8.35% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.14% on the day, quoting at 23515.85. The Sensex is at 74689.48, down 0.12%. Wockhardt Ltd has gained around 54.46% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has gained around 3.41% in last one month and is currently quoting at 24345.8, down 0.28% on the day. The volume in the stock stood at 84.82 lakh shares today, compared to the daily average of 40.05 lakh shares in last one month.The PE of the stock is 113.01 based on TTM earnings ending March 26.Powered by Capital Market - Live

Investor sentiment has remained strong following regulatory milestones for the drug. The stock has rallied 37.58% over the past week, surged 61.72% in the last month and gained 58.63% so far in 2026. The novel intravenous antibiotic is indicated for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis. The approval marks a major milestone for the Mumbai-based drug maker, coming just days after the antibiotic received marketing approval in India on 27 May 2026. According to the company, ZAYNICH is the first new chemical entity fully discovered, developed and commercialised by an Indian pharmaceutical company to secure U.S. FDA approval. ZAYNICH combines cefepime, a fourth-generation cephalosporin antibiotic, with zidebactam, a novel beta-lactam enhancer. The therapy is designed to tackle multidrug-resistant Gram-negative bacteria, including strains that have become resistant to many currently available antibiotics. The FDA approval was supported by data from the global Phase 3 ENHANCE-1 study involving 530 patients across 64 sites worldwide. In the trial, ZAYNICH achieved a combined clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem, a commonly used antibiotic. The drug has also received Qualified Infectious Disease Product (QIDP), Fast Track and Priority Review designations from the U.S. regulator. Wockhardt said more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths, highlighting the need for new treatment options. The company has also filed a marketing authorisation application for the product with the European Medicines Agency. Wockhardt is a research-driven global pharmaceutical and biotechnology company focused on developing anti-infective therapies. The company currently has six antibiotics at various stages of development and commercialisation, all of which have received QIDP designation from the US FDA. Wockhardt reported a consolidated net profit of Rs 164 crore in Q4 FY26, compared with a net loss of Rs 45 crore in the corresponding quarter last year. Revenue from operations increased 29.87% YoY to Rs 965 crore during the quarter. Powered by Capital Market - Live

The approval was granted by the Central Drugs Standard Control Organisation (CDSCO) and marks a significant milestone for the company's antibiotic research programme. Zaynich is an indigenously discovered and developed antibiotic that combines Zidebactam, a beta-lactam enhancer antibiotic, with Cefepime, a cephalosporin antibacterial drug. The approval is backed by results from the global Phase 3 ENHANCE-1 clinical trial, which compared Zaynich with meropenem in patients suffering from complicated urinary tract infections. The study showed that 89% of patients treated with Zaynich achieved the primary endpoint of clinical cure and microbiological eradication, compared with 68.4% of patients receiving meropenem. Among patients with concurrent bacteremia, the composite response rate at the test-of-cure visit was 89% for Zaynich, compared with 44% for meropenem, highlighting its potential effectiveness in severe infections. Before entering Phase 3 trials, the drug was evaluated in nine Phase 1 studies and a Phase 2 trial involving patients with documented meropenem-resistant Gram-negative infections. The Phase 2 study, conducted across 15 tertiary care hospitals in India, reported clinical efficacy of more than 97% across serious infections, including hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, bloodstream infections and complicated intra-abdominal infections. Wockhardt said Zaynich could address a critical unmet need in the treatment of carbapenem-resistant and extensively drug-resistant Gram-negative infections, particularly those driven by metallo-beta-lactamase (MBL) resistance mechanisms, which are prevalent in India. The company has also submitted a New Drug Application for Cefepime/Zidebactam in the United States and a Marketing Authorisation Application in the European Union. Both applications are currently under regulatory review. The drug has previously received Priority Review, Fast Track and Qualified Infectious Disease Product (QIDP) designations from the US Food and Drug Administration. Wockhardt is a research-driven global pharmaceutical and biotechnology company focused on developing anti-infective therapies. The company currently has six antibiotics at various stages of development and commercialisation, all of which have received QIDP designation from the US FDA. On a consolidated basis, the company reported a net profit of Rs 164 crore in Q4 FY26, reversing a loss of Rs 45 crore in the year-ago period. PAT surged 168.85% QoQ from Rs 61 crore in Q3 FY26. Revenue from operations rose 29.87% YoY to Rs 965 crore in Q4 FY26, while increasing 8.67% QoQ from Rs 888 crore. Powered by Capital Market - Live

Wockhardt Ltd gained for a third straight session today. The stock is quoting at Rs 1739.5, up 2.31% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.07% on the day, quoting at 23930.5. The Sensex is at 75999.31, down 0.01%. Wockhardt Ltd has risen around 22.73% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has risen around 6.68% in last one month and is currently quoting at 24659.2, up 0.19% on the day. The volume in the stock stood at 12 lakh shares today, compared to the daily average of 31.15 lakh shares in last one month.The PE of the stock is 94.82 based on TTM earnings ending March 26.Powered by Capital Market - Live

Wockhardt has received upgrade in credit rating from ICRA BBB; Positive / ICRA A3+ to ICRA A-; Stable / ICRA A2+.

Wockhardt will hold a meeting of the Board of Directors of the Company on 4 May 2026.

Wockhardt Ltd gained for a fifth straight session today. The stock is quoting at Rs 1422, up 1.02% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.64% on the day, quoting at 24418.45. The Sensex is at 78624.59, down 0.82%. Wockhardt Ltd has risen around 29.24% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has risen around 1.77% in last one month and is currently quoting at 22438.45, up 0.02% on the day. The volume in the stock stood at 3.55 lakh shares today, compared to the daily average of 8.14 lakh shares in last one month.The PE of the stock is 113.78 based on TTM earnings ending December 25.

Wockhardt Ltd gained for a fifth straight session today. The stock is quoting at Rs 1344.5, up 3.61% on the day as on 12:39 IST on the NSE. The benchmark NIFTY is up around 3.46% on the day, quoting at 23923.45. The Sensex is at 77391.97, up 3.72%. Wockhardt Ltd has risen around 5.93% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has risen around 4.3% in last one month and is currently quoting at 21868.7, up 0.36% on the day. The volume in the stock stood at 4.26 lakh shares today, compared to the daily average of 7.17 lakh shares in last one month.The PE of the stock is 104.83 based on TTM earnings ending December 25.

The recommendation clears the path for final approval by the Drugs Controller General of India. The recommendation follows a comprehensive evaluation of the drug's clinical dossier, including nine phase-1 studies, a phase-2 study in meropenem-resistant infections, and a global phase-3 trial in complicated urinary tract infections and acute pyelonephritis, along with data from compassionate-use cases. In the phase-3 study, zidebactam/cefepime demonstrated superiority over meropenem in combined clinical and microbiological cure, indicating strong efficacy against resistant pathogens. Zaynich is based on a novel beta-lactam enhancer mechanism targeting MDR/XDR gram-negative bacteria, addressing a critical unmet need in anti-infective therapy. The asset has been developed over 15 years and is supported by a large body of clinical and real-world evidence, including use in severe infections such as hospital-acquired pneumonia and bloodstream infections. The company further said that regulatory filings for the product have already been submitted in the United States and European Union and are currently under advanced stages of review. Wockhardt is a global pharmaceutical and biotechnology company focused on developing innovative anti-infective solutions. The company's consolidated net profit surged to Rs 59 crore in the quarter ended December 2025 as against Rs 14 crore during the previous quarter ended December 2024. Sales rose 23.16% to Rs 888 crore in Q3 FY26 as compared with Q3 FY25. The scrip fell 1.05% to currently trade at Rs 1176.60 on the BSE. Powered by Capital Market - Live